Non-Segmental Vitiligo (NSV)MEASUREAAVitHSNCT07136467
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
An observational study of Non-Segmental Vitiligo (NSV) and Alopecia Areata, run by AbbVie at 116 sites in 18 countries.
Trial summary
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- How many people
- 2,795 participants
- Where
- 116 sitesin 18 countries
- Study dates
- 2 Sep 2025to Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Adolescent and Adult Participants with Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa in Real-World will undergo a single-visit data collection per routine clinical practice.
Who may be able to join
- Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
- Participants Ability to understand study questionnaires, with caregiver support as required for adolescents
Who cannot join
- Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
- Unable or unwilling to comply with study requirements and PRO collection
Trial locations and contacts
116 sites in 18 countries. Contact the study team or a site near you to ask about taking part.
116 sites in 18 countries
France22 sites, 22 recruiting
- Recruiting
Centre Hospitalier Regional Universitaire de Besancon - Hopital Jean Minjoz /ID# 277459
Besançon, Doubs, 25000
- Recruiting
Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-Andre /ID# 277322
Bordeaux, Gironde, 33000
- Recruiting
Centre Hospitalier de Calais /ID# 277320
Calais, 62100
- Recruiting
Centre Hospitalier Régional Universitaire De Tours - Hôpital Trousseau /ID# 277545
Chambray-lès-Tours, Indre-et-Loire, 37170
- Recruiting
Centre Hospitalier Public du Cotentin - Hôpital Pasteur /ID# 279613
Cherbourg, 50102
- Recruiting
Chu Dijon /Id# 277493
Dijon, Bourgogne-Franche-Comté, 21000
- Recruiting
Centre Hospitalier Departemental Vendee (Chd Vendee) /ID# 277317
La Roche-sur-Yon, Vendee, 85925
- Recruiting
CHU Grenoble - Hopital Michallon /ID# 277501
La Tronche, Isere, 38700
- Recruiting
CHU Limoges - Dupuytren 2 /ID# 277323
Limoges, New Aquitaine, 87000
- Recruiting
Centre Hospitalier de Bretagne Sud /ID# 277559
Lorient, Morbihan, 56322
- Recruiting
Centre Hospitalier Régional Metz Thionville - Hôpital de Mercy /ID# 277792
Metz, Moselle, 57085
- Recruiting
Groupe Hospitalier Du Havre - Hôpital Jacques Monod /ID# 277506
Montivilliers, Seine-Maritime, 76290
- Recruiting
Cideazur /ID# 277316
Nice, 06000
- Recruiting
Centre De Santé Sabouraud /ID# 278409
Paris, 75010
- Recruiting
Groupe Hospitalier Paris Saint-Joseph /ID# 278270
Paris, 75014
- Recruiting
CHU Rennes - Hôpital PONTCHAILLOU /ID# 277527
Rennes, Ille-et-Vilaine, 35000
- Recruiting
CHU de la reunion /ID# 277318
Saint-Denis, 97400
- Recruiting
Hôpital d'Instruction des Armées Bégin /ID# 278135
Saint-Mandé, 94163
- Recruiting
Hôpital d'Instruction des Armées Sainte-Anne /ID# 277458
Toulon, Var, 83800
- Recruiting
CHU Toulouse - Hopital Larrey /ID# 277321
Toulouse, Haute-Garonne, 31400
- Recruiting
Hopital Nord Franche-Comté /ID# 277560
Trévenans, Territoire De Belfort, 90400
- Recruiting
Médipôle Lyon-Villeurbanne /ID# 277526
Villeurbanne, Rhone, 69100
Germany21 sites, 21 recruiting
- Recruiting
Hautarztliche Gemeinschaftspraxis Dres. med. Petri & Mocklinghoff /ID# 279230
Ahaus, North Rhine-Westphalia, 48683
- Recruiting
Private Practice - Dr. Virgil Oreste Mihaescu /ID# 279229
Augsburg, Bavaria, 86150
- Recruiting
MVZ medicum.mittelhessen /ID# 279136
Bad Camberg, 65520
- Recruiting
Mvz Corius Biberach Gmbh /Id# 281157
Biberach an der Riss, Baden-Wurttemberg, 88400
- Recruiting
Studienzentrum an der Hase GbR Dr. Weyergraf/Dr. Frick/Thomas Heiber /ID# 279210
Bramsche, Lower Saxony, 49565
- Recruiting
Private Practice - Dr. Petra Hausler-Mehlhorn /ID# 280434
Chemnitz, Saxony, 09130
- Recruiting
Private Practice - Dr. Dirk Lange /ID# 279215
Gera, Thuringia, 07548
- Recruiting
Hautarztpraxis Shirin Samimi-Fard & Elena Dippel /ID# 279232
Gladbeck, North Rhine-Westphalia, 45964
- Recruiting
Private Practice - Dr. Abdou Zarzour /ID# 279125
Halle, Saxony-Anhalt, 06108
- Recruiting
Hautarztpraxis Hassberge Dr. Boris Bauer /ID# 279272
Haßfurt, Bavaria, 97437
- Recruiting
Derma Sana /ID# 279254
Karlsruhe, Baden-Wurttemberg, 76133
- Recruiting
Dr. Neumann /ID# 279255
Kelheim, Bavaria, 93309
- Recruiting
Dermakulm /Id# 279126
Kulmbach, Bavaria, 95326
- Recruiting
Hautarztpraxis Dr. Med. Ulrike Wiemers / Dr. Med. Franca Wiemers /ID# 279124
Leipzig, 04317
- Recruiting
Dermatologie Quist-BAG Dres. med. Quist PartG /ID# 279271
Mainz, Rhineland-Palatinate, 55128
- Recruiting
HMS GmbH Zimmer /ID# 279211
Merzig, Saarland, 66663
- Recruiting
ZENTderma /ID# 279235
Mönchengladbach, North Rhine-Westphalia, 41061
- Recruiting
Private Practice - Dr. Dariusch Mortazawi /ID# 279214
Remscheid, North Rhine-Westphalia, 42897
- Recruiting
Hautarztpraxis Schwelm /ID# 279140
Schwelm, 58332
- Recruiting
Praxis Dehmel / Brand-Opitzer /ID# 279351
Wasserburg A. Inn, 83512
- Recruiting
Dr. med. Nicola Möller & Thomas Kurtenbach GbR Dermatologie im Zentrum /ID# 279137
Wiesbaden, 65185
Switzerland10 sites, 10 recruiting
- Recruiting
Kantonsspital Aarau /ID# 276810
Aarau, Canton of Aargau, 5001
- Recruiting
University Hospital Basel /ID# 276716
Basel Town, Canton of Basel-City, 4031
- Recruiting
Ospedale Regionale Bellinzona E Valli /ID# 277964
Bellinzona, Canton Ticino, 6501
- Recruiting
Inselspital, Universitaetsspital Bern /ID# 276718
Bern, 3010
- Recruiting
Cabinet Dr Damjan Nikolic, Clinique du Seujet /ID# 278467
Geneva, Canton of Geneva, 1201
- Recruiting
Hopitaux Universitaires de Geneve /ID# 277950
Geneva, Canton of Geneva, 1205
- Recruiting
Luzern Kantonsspital /ID# 276813
Lucerne, Canton of Lucerne, 6000
- Recruiting
Studio Medico Dr. Pelloni Francesco /ID# 277948
Lugano, Canton Ticino, 6900
- Recruiting
Basile Darbellay SA /ID# 276811
Orsières, Valais, 1937
- Recruiting
Praxis Dr. med. Pierre de Viragh /ID# 276855
Zurich, Canton of Zurich, 8002
Canada9 sites, 9 recruiting
- Recruiting
Simcoderm Medical And Surgical Dermatology Centre /ID# 276838
Barrie, Ontario, L4M 7G1
- Recruiting
Dermatology Research Institute - Blackfoot Trail /ID# 276548
Calgary, Alberta, T2J 7E1
- Recruiting
Rejuvenation Dermatology - Edmonton Downtown /ID# 276593
Edmonton, Alberta, T5J 3S9
- Recruiting
Alberta Dermatology Consultants /ID# 277187
Edmonton, Alberta, T5N 1L5
- Recruiting
Brunswick Dermatology Center /ID# 276546
Fredericton, New Brunswick, R3M 3Z4
- Recruiting
DermEffects /ID# 276594
London, Ontario, N6H 5L5
- Recruiting
Lynderm Research Inc /ID# 276595
Markham, Ontario, L3P 1X2
- Recruiting
Dermacentre Recherches /Id# 277593
Pointe-Claire, Quebec, H9R 5M7
- Recruiting
York Dermatology Clinic & Research Centre /ID# 276697
Richmond Hill, Ontario, L4C 9M7
United Kingdom8 sites, 8 recruiting
- Recruiting
Ulster Hospital - South Eastern Health & Social Care Trust /ID# 279191
Belfast, BT16 1RH
- Recruiting
Cardiff and Vale UHB /ID# 278856
Cardiff, CF14 4XW
- Recruiting
Leeds Teaching Hospitals NHS Trust /ID# 278524
Leeds, West Yorkshire, LS9 7TF
- Recruiting
University Hospital Lewisham /ID# 279233
London, Greater London, SE13 6LH
- Recruiting
Oxford University Hospitals - John Radcliffe Hospital /ID# 279052
Oxford, Oxfordshire, OX3 9DU
- Recruiting
Mid Yorkshire Teaching NHS Trust /ID# 279190
Wakefield, West Yorkshire, WF1 4DG
- Recruiting
Walsall Manor Hospital /ID# 279240
Walsall, WS2 9PS
- Recruiting
New Cross Hospital /ID# 279202
Wolverhampton, WV10 0QP
Romania7 sites, 7 recruiting
- Recruiting
Institutul Dermato - Estetic /ID# 276296
Bucharest, Bucharest, 010235
- Recruiting
Dr. Carol Davila Central Military Emergency University Hospital /ID# 275818
Bucharest, Bucharest, 010825
- Recruiting
Spitalul Universitar De Urgență Elias /ID# 275806
Bucharest, Bucharest, 011461
- Recruiting
Spitalul Clinic Colentina /ID# 275506
Bucharest, Bucharest, 020125
- Recruiting
Spitalul Clinic Colentina /ID# 275817
Bucharest, Bucharest, 020125
- Recruiting
Spitalul Clinic Judetean de Urgenta Cluj -Napoca /ID# 276837
Cluj-Napoca, Cluj, 400006
- Recruiting
Spitalul Clinic Județean de Urgențe "Sfântul Spiridon" /ID# 276308
Iași, 700111
Greece6 sites, 6 recruiting
- Recruiting
University General Hospital Attikon /ID# 278395
Athens, Attica, 12462
- Recruiting
General Hospital Andreas Syggros /ID# 276969
Athens, Attica, 16121
- Recruiting
The University Hospital of Larissa /ID# 277234
Larissa, Larisa, 41110
- Recruiting
Tzaneio Prefecture General Hospital of Piraeus /ID# 276881
Piraeus, Attica, 18536
- Recruiting
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 277278
Thessaloniki, 54643
- Recruiting
Papageorgiou General Hospital /ID# 277450
Thessaloniki, 56429
Spain6 sites, 6 recruiting
- Recruiting
Hospital Universitario Fundación Alcorcón /ID# 276890
Alcorcón, Madrid, 28922
- Recruiting
Hospital Universitario de Jaén /ID# 276888
Jaén, Jaen, 23007
- Recruiting
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 276731
Majadahonda, Madrid, 28222
- Recruiting
Hospital Universitario Infanta Cristina /ID# 276886
Parla, Madrid, 28981
- Recruiting
Hospital Universitario de Canarias /ID# 276734
San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320
- Recruiting
Hospital Arnau De Vilanova /ID# 276887
Valencia, 46015
Argentina5 sites, 5 recruiting
- Recruiting
Buenos Aires Skin /ID# 277637
Buenos Aires, 1055
- Recruiting
Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 277634
Buenos Aires, 1061
- Recruiting
Hospital Italiano de Buenos Aires /ID# 277636
Buenos Aires, 1181
- Recruiting
Instituto de Neumonología y Dermatología /ID# 277635
Buenos Aires, 1425
- Recruiting
Hospital Britanico de Buenos Aires /ID# 278940
Ciudad Autonoma de Buenos Aire, Buenos Aires, 1280
Japan4 sites, 4 recruiting
- Recruiting
Nagomi Dermatology Clinic /ID# 279997
Ebina-shi, Kanagawa, 243-0432
- Recruiting
Inokashira Park Skin Clinic /ID# 279276
Mitaka-shi, Tokyo, 1810013
- Recruiting
Shinsaibashi Inui Dermatology Clinic /ID# 280564
Osaka, Osaka, 542-0081
- Recruiting
Omori Ekimae Dermatology Clinic /ID# 279277
Ōta-ku, Tokyo, 143-0016
Czechia3 sites, 3 recruiting
- Recruiting
Dermafit Centrum /ID# 275863
Pilsen, Plzeň Region, 323 00
Site Coordinator, +420 377 534 145
- Recruiting
Nemocnice Na Bulovce /ID# 275542
Prague, Central Bohemia, 180 81
- Recruiting
Dermamedest /ID# 275861
Prague, Praha 2, 120 00
Site Coordinator, +420 604 137 738
Italy3 sites, 3 recruiting
- Recruiting
A.O.U. Consorziale Policlinico di Bari /ID# 276857
Bari, 70124
- Recruiting
Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale S.Anna /ID# 276986
Cona, Ferrara, 44124
- Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 277745
Rome, Roma, 00168
Puerto Rico3 sites, 3 recruiting
- Recruiting
Dermatologia Borinquen LLC /ID# 276802
Caguas, 00725
- Recruiting
Dr. Samuel Sanchez PSC /ID# 276386
Caguas, 00727
- Recruiting
Clinical Research Puerto Rico /ID# 276801
San Juan, 00909
Colombia2 sites, 2 recruiting
- Recruiting
Policlinico Social Del Norte /ID# 280935
Bogotá, Bogota D.C., 110131
- Recruiting
Centro de Inmunología y Genética CIGE SAS /ID# 280793
Medellín, Antioquia, 050012
Estonia2 sites, 2 recruiting
- Recruiting
North Estonia Medical Centre /ID# 276933
Tallinn, Harju, 13419
- Recruiting
Tartu University Hospital /ID# 276932
Tartu, 50406
South Korea2 sites, 2 recruiting
- Recruiting
Yonsei University Health System Severance Hospital /ID# 278972
Seoul, Seoul Teugbyeolsi, 03722
- Recruiting
Yonsei University Health System Severance Hospital /ID# 278973
Seoul, Seoul Teugbyeolsi, 03722
Taiwan2 sites, 2 recruiting
- Recruiting
Tri-Service General Hospital /ID# 279761
Taipei, 114
- Recruiting
Linkou Chang Gung Memorial Hospital /ID# 279760
Taoyuan City, 333
Latvia1 site, 1 recruiting
- Recruiting
Riga 1st Hospital /ID# 276361
Riga, LV-1001
About this study
Official title: Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.
- Keywords
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Medical subject headings
- Alopecia Areata, Hidradenitis Suppurativa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants with Vitiligo | Participants with vitiligo will undergo a single-visit data collection per routine clinical practice | |
| Participants with Alopecia Areata | Participants with alopecia areata will undergo a single-visit data collection per routine clinical practice | |
| Participants with Hidradenitis Suppurativa | Participants with hidradenitis suppurativa will undergo a single-visit data collection per routine clinical practice |
What is being measured
The primary outcome is the main question the study is designed to answer.
Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only
AASIS- is a scale assessing the severity of AA-related symptoms on daily functioning. Each item scored on a 0-10 Likert scale, where 0 = not present and 10 = as bad as you can imagine Higher total score = greater impact
Measured: Up to Day 1
Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only
SALT is a Tool developed to quantify AA-related hair loss Total score of 0-100, with 0 = no hair loss, and 100 = complete hair loss
Measured: Up to Day 1
Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only
F-VASI is a quantitative scoring tool used to evaluate the extent and severity of facial vitiligo calculated by multiplying the degree of skin depigmentation of the face
Measured: Up to Day 1
Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only
VitiQoL is a 16-item instrument assessing impact of vitiligo on QoL. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"
Measured: Up to Day 1
Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only
CDLQI is a10-question index measuring health-related quality of life (HRQoL) over the last 7 days for patients suffering from a skin disease. The DLQI is used in participants aged 16 and over and the CDLQI has been validated from the ages of 4 to 16 years. Each item scored on a 4-point Likert scale, where 0 = not at all/not relevant/question unanswered and 3 = very much. Maximum total score = 30 (highest impact on QoL).
Measured: Up to Day 1
Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only
The IHS4 score is calculated as follows: number of nodules (multiplied by 1) + number of abscesses (multiplied by 2) + number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.
Measured: Up to Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2025
- Study start2 Sep 2025
- Primary completionAug 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Segmental Vitiligo (NSV)Studies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 2,795 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07136467
- Sponsor's protocol ID
- H25-663
- Acronym
- MEASUREAAVitHS
- Status last verified
- Feb 2026
- First submitted
- 31 Jul 2025
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)
- ClinicalTrials.gov ID
- NCT07136467
- Acronym / sponsor ID
- MEASUREAAVitHS / H25-663
- Keywords
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,795 participants (estimated)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 2 Sep 2025 (actual)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 22 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Participants with Vitiligo | – | –Participants with vitiligo will undergo a single-visit data collection per routine clinical practice |
| Participants with Alopecia Areata | – | –Participants with alopecia areata will undergo a single-visit data collection per routine clinical practice |
| Participants with Hidradenitis Suppurativa | – | –Participants with hidradenitis suppurativa will undergo a single-visit data collection per routine clinical practice |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adolescent and Adult Participants with Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa in Real-World will undergo a single-visit data collection per routine clinical practice.
Key inclusion criteria (2 listed)
- Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
- Participants Ability to understand study questionnaires, with caregiver support as required for adolescents
Key exclusion criteria (2 listed)
- Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
- Unable or unwilling to comply with study requirements and PRO collection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only
Time frame: Up to Day 1
AASIS- is a scale assessing the severity of AA-related symptoms on daily functioning. Each item scored on a 0-10 Likert scale, where 0 = not present and 10 = as bad as you can imagine Higher total score = greater impact
Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only
Time frame: Up to Day 1
SALT is a Tool developed to quantify AA-related hair loss Total score of 0-100, with 0 = no hair loss, and 100 = complete hair loss
Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only
Time frame: Up to Day 1
F-VASI is a quantitative scoring tool used to evaluate the extent and severity of facial vitiligo calculated by multiplying the degree of skin depigmentation of the face
Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only
Time frame: Up to Day 1
VitiQoL is a 16-item instrument assessing impact of vitiligo on QoL. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"
Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only
Time frame: Up to Day 1
CDLQI is a10-question index measuring health-related quality of life (HRQoL) over the last 7 days for patients suffering from a skin disease. The DLQI is used in participants aged 16 and over and the CDLQI has been validated from the ages of 4 to 16 years. Each item scored on a 4-point Likert scale, where 0 = not at all/not relevant/question unanswered and 3 = very much. Maximum total score = 30 (highest impact on QoL).
Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only
Time frame: Up to Day 1
The IHS4 score is calculated as follows: number of nodules (multiplied by 1) + number of abscesses (multiplied by 2) + number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Non-Segmental Vitiligo (NSV)
RecruitingPhase 2
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
Non-Segmental Vitiligo (NSV)
RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Vitiligo, Non-Segmental Vitiligo (NSV)
RecruitingObservational study
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
Non-Segmental Vitiligo (NSV)
RecruitingPhase 2
Study of D-2570 in Subjects With Non-Segmental Vitiligo
Vitiligo, Non-Segmental Vitiligo (NSV)
Not yet recruitingPhase 2
Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo
Non-Segmental Vitiligo (NSV)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
ABBVIE INC. study director
AbbVie
116 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-Segmental Vitiligo (NSV) and Alopecia Areata, run by AbbVie at 116 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 116 sites in France, Germany, Switzerland, Canada, United Kingdom and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Beth Rycroft (844-663-3742, beth.rycroft@abbvie.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only (time frame: Up to Day 1). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026; AzTrials last refreshed its copy on 26 Oct 2026.